TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25205061

Group type: EXPERIMENTAL
Intervention: Uneventful small incision cataract surgery (SICS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Uneventful phacoemulsification
Number of subjects: 200
Study: 22951047

Group type: EXPERIMENTAL
Intervention: Sentinel node resection (SNR)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Axillary dissection (AD)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 744
Study: 21859932

Group type: EXPERIMENTAL
Intervention: 60 mg/kg azithromycin extended-release (ER)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 30 mg/kg azithromycin immediate-release (IR)
Number of subjects: 38
Study: 18049093

Group type: EXPERIMENTAL
Intervention: 18F‐Flurodeoxyglucose positron emission tomography (FDG PET)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (age-matched and sex-matched subjects without neurological/psychiatric disease)
Number of subjects: 29
Study: 17148533

Group type: EXPERIMENTAL
Intervention: Imputation methods (including last value carried forward, regression procedures, and simple mean)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete case analysis, imputation, and modelling procedures
Number of subjects: 0
Study: 12829523

Group type: EXPERIMENTAL
Intervention: Treated hypertensive group
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Untreated hypertensive group
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Clinical groups comparison
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Treated hypertensive group vs Untreated hypertensive group
Number of subjects: 1249
Study: 10687982

Group type: EXPERIMENTAL
Intervention: Digital rectal examination and transrectal ultrasonography at PSA 0 to 4.0 ng/ml
Number of subjects: 9211

Group type: EXPERIMENTAL
Intervention: PSA 2 to 4 ng/ml
Number of subjects: 9211

Group type: EXPERIMENTAL
Intervention: PSA 0 to 4 ng/ml
Number of subjects: 9211
Study: 9322122

Group type: EXPERIMENTAL
Intervention: Serum cytokeratin 19 levels > 2 ng/mL in pancreatic duct cell carcinoma
Number of subjects: 123

Group type: COMPARATOR
Intervention: Serum cytokeratin 19 levels in chronic pancreatitis
Number of subjects: 123

Group type: COMPARATOR
Intervention: Serum cytokeratin 19 levels in islet cell tumors
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sensitivity of cytokeratin 19 assay
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Immunohistochemical expression of cytokeratin 19
Number of subjects: 123
Study: 8195846

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 2291

Group type: COMPARATOR
Intervention: Comparative agents (ampicillin, amoxicillin, cephalosporins, erythromycin, doxycycline, chloramphenicol)
Number of subjects: 2291
Study: 3026016

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin (50 mg/kg per day, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: sulbactam/penicillin (1:1.2 or 1:1.8 ratio, intravenous bolus injection at 6-hr intervals for four to 11 days, mean duration 9 days)
Number of subjects: 23
Study: 30676382

Group type: EXPERIMENTAL
Intervention: IV-PCA enhanced with ketorolac/diclofenac
Number of subjects: 143

Group type: COMPARATOR
Intervention: TEA
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: IV-PCA
Number of subjects: 143
Study: 29169916

Group type: EXPERIMENTAL
Intervention: Lissamine green solution (GreenGlo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lissamine green solution (Lissaver)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPGreen solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single versus double drop instillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated lid evertion
Number of subjects: 0
Study: 26783292

Group type: EXPERIMENTAL
Intervention: 4.5% nicotine electronic cigarette
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo electronic cigarette
Number of subjects: 99
Study: 25002661

Group type: EXPERIMENTAL
Intervention: PEG‐CS+Bisacodyl
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: PEG‐Asc
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: NaPico+MgCit
Number of subjects: 299

Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 299
Study: 22834681

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (30 ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 42
Study: 21163117

Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m² twice daily plus weekly docetaxel 30 mg/m² on days 1 and 8 every 21 days
Number of subjects: 41
Study: 17481878

Group type: EXPERIMENTAL
Intervention: RTube
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EcoScreen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Storage for 8 weeks
Number of subjects: 23
Study: 15928658

Group type: EXPERIMENTAL
Intervention: Capecitabine 500 mg m(‐2) b.i.d.(‐1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Capecitabine 625 mg m(‐2) b.i.d.(‐1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, 5-Fluorouracil (ECF)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Epirubicin, Oxaliplatin, 5-Fluorouracil (EOF)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, Capecitabine (ECX)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Epirubicin, Oxaliplatin, Capecitabine (EOX)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Fluorouracil (F)
Number of subjects: 204
Study: 15497659

Group type: EXPERIMENTAL
Intervention: Pegvisomant 10 mg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant 15 mg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant 20 mg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 10571718

Group type: EXPERIMENTAL
Intervention: Mailed educational brochure
Number of subjects: 740

Group type: COMPARATOR
Intervention: Postcard reminder
Number of subjects: 740
Study: 8737522

Group type: EXPERIMENTAL
Intervention: Thromboembolism prophylaxis with acenocoumarol during radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMW heparin during radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acenocoumarol during radiation therapy
Number of subjects: 0
Study: 2065389

Group type: EXPERIMENTAL
Intervention: Combination of phentolamine (20‐30 mg/day) and angelicini (150‐450 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional supporting therapy
Number of subjects: 60
Study: 6760236

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxy vitamin D3
Number of subjects: 23

Group type: COMPARATOR
Intervention: 24,25-dihydroxy vitamin D3
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Substitution of 1,25-dihydroxy vitamin D3 for 24,25-dihydroxy vitamin D3
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Successful renal transplantation
Number of subjects: 23
Study: 31576438

Group type: EXPERIMENTAL
Intervention: Hyperoxia during CPB (inspired fraction of oxygen of one to one)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard care (oxygen to achieve partial arterial blood pressure less than 150 mmHg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Hyperoxia during CPB
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 330
Study: 30684340

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 84
Study: 25892654

Group type: EXPERIMENTAL
Intervention: Endurance training combined with heavy strength training (E+S)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal endurance training only (E)
Number of subjects: 19
Study: 23721658

Group type: EXPERIMENTAL
Intervention: Training of primary health care workers in mental health using a specially designed toolkit
Number of subjects: 3437

Group type: COMPARATOR
Intervention: Control arm (no training)
Number of subjects: 3437
Study: 22818729

Group type: EXPERIMENTAL
Intervention: Variety of vegetables (200 g of each of broccoli, carrots, and snap peas)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Single vegetable servings (600 g of broccoli, carrots, or snap peas)
Number of subjects: 66
Study: 20558324

Group type: EXPERIMENTAL
Intervention: Right Ventricular Apex (RVA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Right Ventricular Outflow Tract (RVOT)
Number of subjects: 33
Study: 17437242

Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin‐6 (IL‐6)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin‐1β (IL‐1β)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High sensitive C‐reactive protein (CRP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maternal blood samples with histologic chorioamnionitis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maternal blood samples with connatal infection
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maternal blood samples with periventricular leukomalacia (PVL)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pregnancies with preterm premature rupture of membranes (PPROM)
Number of subjects: 47
Study: 16260697

Group type: EXPERIMENTAL
Intervention: TMZ + IFN-alpha
Number of subjects: 294

Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 294
Study: 12149599

Group type: EXPERIMENTAL
Intervention: Acarbose (2 x 50 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10215302

Group type: EXPERIMENTAL
Intervention: Chronic estrogen replacement therapy
Number of subjects: 122
Study: 7793735

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg IV over 30 minutes, followed by 1 mg/kg/hr infusion for 12 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline of equal volume)
Number of subjects: 30
Study: 2323324

Group type: EXPERIMENTAL
Intervention: High-choice decisional control manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-choice decisional control manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management and action instructions (given to all students)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported work orientation
Number of subjects: 0
Study: 43338

Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 10
Study: 31280967

Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg subcutaneously at weeks 0 and 4)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Adalimumab (80 mg subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Adalimumab (40 mg)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Risankizumab (150 mg)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Adverse events reported in risankizumab group
Number of subjects: 605

Group type: COMPARATOR
Intervention: Adverse events reported in adalimumab group
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Adverse events reported in risankizumab group (part B)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Adverse events reported in adalimumab group (part B)
Number of subjects: 605
Study: 29798119

Group type: EXPERIMENTAL
Intervention: Sleep apnea monitoring management platform
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional CPAP card reader mode
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 26704894

Group type: EXPERIMENTAL
Intervention: Exercise group (N = 382) training 3 days/week (50-55 min/session) from gestational weeks 9-11 until weeks 38-39.
Number of subjects: 765
Study: 24714776

Group type: EXPERIMENTAL
Intervention: Carboplatin, Paclitaxel, and Sorafenib (CPS)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Carboplatin and Paclitaxel (CP)
Number of subjects: 179
Study: 22040525

Group type: EXPERIMENTAL
Intervention: Fermented soybean milk (FSM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-fermented soybean milk (NFSM)
Number of subjects: 10
Study: 19888035

Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Transdermal estradiol gel (1 mg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Oral estradiol with daily medroxyprogesterone acetate
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 17590369

Group type: EXPERIMENTAL
Intervention: 1 injection of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2 injections of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3 injections of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42
Study: 15632778

Group type: EXPERIMENTAL
Intervention: Unsupported upper limb endurance training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lower limb training alone (control group)
Number of subjects: 38
Study: 11720682

Group type: EXPERIMENTAL
Intervention: Sentinel node surgery without axillary dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 0
Study: 9177594

Group type: EXPERIMENTAL
Intervention: Stationary cycle (low movement)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Walking (medium movement)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Aerobic movement (high movement)
Number of subjects: 106
Study: 7584261

Group type: EXPERIMENTAL
Intervention: Spontaneous recollections of intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly sampled occasions
Number of subjects: 0
Study: 3318539

Group type: EXPERIMENTAL
Intervention: alpha‐fluoromethyl histidine, 100 mg twice daily for 3 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: alpha‐fluoromethyl histidine
Number of subjects: 13
Study: 28925009

Group type: EXPERIMENTAL
Intervention: Personal-preferred exercise modalities (PPEMs)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no extra exercise)
Number of subjects: 94
Study: 26831168

Group type: EXPERIMENTAL
Intervention: 62.7 ± 3.1 g of IgG IV in 2.6 ± 0.3 L of plasma within 6 h after birth
Number of subjects: 28

Group type: COMPARATOR
Intervention: 4 L of high quality colostrum within 12 h of birth
Number of subjects: 28
Study: 25651956

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (5 mL 1 % Naropin(®))
Number of subjects: 87

Group type: COMPARATOR
Intervention: Saline (5 mL)
Number of subjects: 87
Study: 23095606

Group type: EXPERIMENTAL
Intervention: Liquefaction (LG)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Torsional IP (TG)
Number of subjects: 95
Study: 21910713

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ at weeks 0, 2, 6, 14 and 22
Number of subjects: 868

Group type: COMPARATOR
Intervention: Methotrexate 15 mg weekly (increased to 20 mg weekly at week 6 if PASI response < 25%)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Infliximab (after switching from MTX at week 16)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 868
Study: 18165000

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 12548587

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (clodronate or pamidronate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study: 9754791

Group type: EXPERIMENTAL
Intervention: Drug treatment (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8549083

Group type: EXPERIMENTAL
Intervention: Selenium treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Number of subjects: 109
Study: 2794708

Group type: EXPERIMENTAL
Intervention: Eutrophic electrotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniform 10 Hz electrotherapy
Number of subjects: 0
Study: 830945

Group type: EXPERIMENTAL
Intervention: Overweight video version of the patient interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight video version of the patient interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audio version of the patient interview (both normal and overweight)
Number of subjects: 0
Study: 30635936

Group type: EXPERIMENTAL
Intervention: Neuromyelitis optica patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fulfillment of at least 2 of 5 criteria
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: MRI findings and criteria performance
Number of subjects: 116
Study: 28368437

Group type: EXPERIMENTAL
Intervention: PM01183 at 7.0 mg flat dose every 3 weeks (q3wk)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PM01183
Number of subjects: 81

Group type: COMPARATOR
Intervention: Topotecan (days 1-5 q3wk or weekly q4wk)
Number of subjects: 81
Study: 25933919

Group type: EXPERIMENTAL
Intervention: Psychotherapy A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23966309

Group type: EXPERIMENTAL
Intervention: Idraparinux (fixed-dose)
Number of subjects: 4576

Group type: COMPARATOR
Intervention: Conventional anticoagulation (dose-adjusted vitamin K antagonists)
Number of subjects: 4576

Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc score 1-2
Number of subjects: 4576

Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc or CHADS2 scores
Number of subjects: 4576
Study: 21417594

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP) plus myo-inositol (MI) 4 g/die for 12 months
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP) plus myo-inositol (MI)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Combined oral contraceptive pill (OCP) alone
Number of subjects: 155
Study: 18802361

Group type: EXPERIMENTAL
Intervention: Cluster schedule of specific immunotherapy (6-week duration)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional schedule of specific immunotherapy (14-week duration)
Number of subjects: 96
Study: 17490567

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2
Study: 15250225

Group type: EXPERIMENTAL
Intervention: Bronchofiberscopic (BF) injection of 4% lidocaine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lidocaine sprayed from a 1.06 mm catheter through the BF channel
Number of subjects: 26
Study: 11526793

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rehabilitation facilities (for Schizophrenia)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neurotic disorders
Number of subjects: 75

Group type: COMPARATOR
Intervention: Inpatient services and drugs administration
Number of subjects: 75
Study: 9771513

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 40
Study: 7835013

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omnivorous diet (Control)
Number of subjects: 0
Study: 3341209

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DDD pacing (crossover subgroup)
Number of subjects: 19

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 19
Study: 29857009

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Palmitic acid, LPS, or TNF‐α
Number of subjects: 23

Group type: COMPARATOR
Intervention: Obese asthmatic patients
Number of subjects: 23
Study: 28342741

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 26672587

Group type: EXPERIMENTAL
Intervention: Vertical tunnel-based low-site PD catheter implantation (n = 48)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Traditional catheter implantation by open surgery (n = 41)
Number of subjects: 89
Study: 23663021

Group type: EXPERIMENTAL
Intervention: Research-based intervention on clinical supervision, consisting of three sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational preparation for supervision and systematic reflection on supervision.
Number of subjects: 0
Study: 22287431

Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo (2 sprays/nostril once daily)
Number of subjects: 506
Study: 19297072

Group type: EXPERIMENTAL
Intervention: Pre-operative treatment with triptorelin depot (GnRH-a)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 33
Study: 17846552

Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 0
Study: 15474813

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 11723431

Group type: EXPERIMENTAL
Intervention: Diclofenac mouthwash (0.074%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50